CA-OMNI-CONVERSION
22.4.2021 06:10:08 CEST | Business Wire | Press release
Today, OMNI Conversion Technologies Inc. (OMNI CT) announced the first sale of its unprecedented waste to hydrogen product. The Larsen and Lam Climate Initiative, a foundation backed by philanthropists Chris Larsen and Lyna Lam, has committed $35 million to bring this ground-breaking technology to production in the fight against climate change. The first commercial plant in production from OMNI CT will use unsorted non-recyclable Municipal Solid Waste (MSW), which is currently disposed of in landfills, to produce negative carbon hydrogen in California.
New technologies are essential in the fight against climate change. While low-cost solar electricity was a dream only a decade ago, its impact today is far-reaching. The Larsen and Lam Climate Initiative investment will accelerate the global adoption of OMNI CT technology.
”Low or zero CO2 fuels are critical to achieving a decarbonized economy. OMNI CT has created a first-of-its-kind product that can have a global and immediate impact. This is why we are excited to work with their team to bring this technology to market in California as our first project from the Larsen and Lam Climate Initiative,” said Chris Larsen, Co-Founder of the Larsen and Lam Climate Initiative and Ripple.
“With surging global interest in hydrogen and biofuels and as the urgency grows around the climate change crisis, it’s an opportune time to be launching our product into the fight against climate change. We’ve spent 15 years and $400 million perfecting it. We’re thrilled to be working with the Larsen and Lam Climate Initiative who not only understand but share our vision for the future,” said Rod Bryden, CEO of OMNI CT.
Professor Daniel Kammen, Chair of the Energy and Resources Group at the University of California, Berkeley, commented that zero-carbon fuels are a critical part of the aggressive path to a clean economy. As California looks to build a vibrant zero-carbon economy, the Omni technology is an exciting addition that will solve multiple problems at once.
The Omni 200™ GPRS™ waste to hydrogen product can produce around 5000 tonnes of negative carbon hydrogen each year, from 200 tonnes a day of unsorted non-recyclable garbage. Hydrogen is produced in the city where it is needed and the garbage is diverted from landfill to OMNI CT and eliminated with no air emissions and nothing left for disposal. Energy in the garbage replaces electricity otherwise required to make green hydrogen. The circular hydrogen produced could operate some 550 city buses running on hydrogen at a cost less than the current cost of using gasoline or diesel.
The purchase was funded and signed on April 21, 2021 with the goal of being in production in California converting Municipal Solid Waste to hydrogen by the end of 2023.
About OMNI CT
OMNI CT is an Ottawa Canada-based company that has developed a proprietary technology by designing, building, testing, and operating a complete commercial demonstration plant from 2007-2014. The patented process converts any solid energetic material into OmniSyngas™ to produce clean green hydrogen, biofuels, synthetic natural gas, chemicals or electricity for the circular economy.
OMNI CT’s robust efficient OMNI200™ GPRS™ is providing a unique solution to achieving decarbonization targets.
The OMNI200™ Gasification & Plasma Refining System (GPRS™)
The OMNI200™ GPRS™ unit is proven at industrial scale. It is a complete integrated system, delivered to site in large modules, rather than stick-built. It receives and converts at a rate of 200 tonnes per day (67,000 tonnes per year) a wide variety and mix of energetic wastes into clean consistent syngas with a predictable heating value and composition. The H2/CO ratio can be tailored to the final application. Multiple units can be readily combined for larger plants.
OmniSyngas™
OmniSyngas™ is a precursor to the production of hydrogen and biofuels. Municipal solid waste has more than 50% biogenic content. This will produce green fuels and avoid methane from sending waste to landfills. Since methane has 25x the GHG effect of CO2, these fuels can be produced with a negative carbon footprint. Further reduction is possible by capturing and storing the CO2 in the syngas.
For additional details on Omni CT’s product: Download Product Description
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421006131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom